Regeneron Pharmaceuticals says Pasatru showed no new HO lesions in FOP
Late-breaking data presented at ASBMR show a consistent safety profile from weeks 56 to 84 of the OPTIMA trial extension.
GetSignal Regeneron Pharmaceuticals REGN
Regeneron Pharmaceuticals announced on October 12, 2026, 84-week results from the Phase 3 OPTIMA trial of Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP). The company said the data show sustained efficacy from weeks 56 to 84. It also said Pasatru is FDA-approved and has shown reductions in both new HO lesions and clinician-assessed flare-ups in a 56-week placebo-controlled trial.
Key facts
- Trial
- Phase 3 OPTIMA trial extension
- Results period
- Weeks 56 to 84
- Presented at
- ASBMR, late-breaking data
Source: The company's release on GlobeNewswire, October 12, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
